U.S. Entertainment Stock News

Franklin Resources stock: context for recent moves Franklin Resources (BEN) has drawn attention after recent share price moves, with the stock closing at $25.78. Investors are weighing this level against its recent returns, profitability, and how the asset manager is currently valued. See our latest analysis for Franklin Resources. Recent trading has been softer, with a 1 day share price return showing a 1.75% decline and a 7 day share price return showing a 4.52% decline. However, the 90 day...

On March 10, 2026, The D. E. Shaw group sent an open letter to CoStar Group’s board criticizing the reorganization of reporting segments, reduced disclosure of Homes.com metrics, and what it views as weaker accountability to shareholders. The activist’s claims that segment changes obscure Homes.com’s weaker performance directly challenge investor confidence in CoStar’s transparency and financial reporting practices. We’ll now explore how this activist criticism of CoStar’s segment reporting...

NANO Nuclear Energy Inc. announced in February 2026 that it signed a Memorandum of Understanding with Abu Dhabi-based EHC Investment L.L.C. to explore a joint venture for deploying its KRONOS MMR™ micro modular reactors and related supply chains in the UAE and potentially the wider Gulf region. The plan to assess data centers, industrial facilities and other energy-intensive sites as potential hosts highlights how NANO Nuclear aims to align its microreactor technology with specific...

CAVA Group (CAVA) has been back in focus after fresh analyst coverage highlighted its role in Mediterranean fast casual dining, alongside mixed but generally positive research opinions that have added context to the stock’s recent move. See our latest analysis for CAVA Group. The recent run in CAVA’s share price, with a 30 day share price return of 16.94% and a 90 day share price return of 54.65%, suggests momentum has been building around the story, even though the 1 year total shareholder...

In early March 2026, Power Integrations disclosed that Director Balu Balakrishnan indirectly sold 10,080 shares in an automatic transaction to cover tax obligations arising from the vesting of restricted stock, alongside previously reported mixed fourth-quarter results and a 7% global workforce reduction under a restructuring plan. This combination of tax-related insider selling and cost-cutting measures highlights how Power Integrations is balancing leadership equity incentives with efforts...

If you are wondering whether J. M. Smucker is attractively priced right now, this article walks through what the current share price could mean for long term investors. The stock closed at US$108.96, with returns of 5% decline over the past 7 days, 0.5% decline over the last 30 days, a 12.8% gain year to date, and a 3.2% decline over the past year. Together, these figures give you a mixed picture of recent sentiment around the company. Recent news coverage has focused on J. M. Smucker as a...

What recent moves in Perella Weinberg Partners (PWP) might mean for investors Perella Weinberg Partners (PWP) has recently drawn attention after a month return of about a 28% decline, extending a negative trend over the past 3 months and year, despite a strong 3 year total return. With the shares last closing at US$16.74 and annual revenue of roughly US$750.9 million alongside net income of about US$35.5 million, the current setup raises questions about how investors weigh short term weakness...

Legend Biotech (LEGN) has released its full year 2025 results, drawing fresh attention as revenue reached US$1,028.9 million while the company recorded a net loss of US$296.8 million and a higher loss per share. See our latest analysis for Legend Biotech. Legend Biotech’s recent full year announcement comes after a mixed run in the market, with a 1 month share price return of 11.93% partly offsetting a 1 year total shareholder return decline of 43.76%. This suggests short term momentum but...

If you are trying to work out whether Vericel is attractively priced today, it helps to step back and look at both its recent share performance and what the numbers say about value. Vericel shares last closed at US$34.12, with returns of 3.5% decline over 7 days, 5.7% decline over 30 days, a 4.2% decline year to date and a 30.2% decline over the last year, while the 3 year return is 15.3% and the 5 year return is 28% decline. Recent price moves sit against a backdrop of ongoing interest in...

Full year 2025 earnings snapshot Tootsie Roll Industries (TR) reported full year 2025 results that showed higher sales, revenue, and net income compared with 2024, giving investors fresh insight into how the candy maker’s operations and profitability are holding up. See our latest analysis for Tootsie Roll Industries. The latest move in Tootsie Roll Industries’ share price, finishing at $42.34, sits alongside a 30 day share price return of 11.0% and a 23.16% year to date share price return...

Parker-Hannifin recently reported strong year-over-year revenue growth in its Aerospace Systems segment, completed acquisitions in filtration and electrification, and lifted its fiscal 2026 earnings estimate on the back of firm commercial and military demand. These moves, alongside higher dividends and sizeable share repurchases, highlight management’s confidence in cash generation and the push toward more resilient, longer-cycle revenue streams. Now we’ll explore how this upgraded earnings...

Mineralys Therapeutics (MLYS) is back in focus after the FDA accepted its New Drug Application for lorundrostat in adult hypertension and set a PDUFA action date of December 22, 2026. See our latest analysis for Mineralys Therapeutics. Despite the NDA milestone, Mineralys Therapeutics’ recent share price performance has been weak, with a 30 day share price return showing an 8.5% decline and a 90 day share price return showing a 25.84% decline. However, its 1 year total shareholder return of...

What the latest AI launch and buyback expansion mean for Stagwell (STGW) Stagwell (STGW) has put AI at the center of its recent updates, pairing higher net revenue and strong free cash flow with an expanded stock repurchase plan and the global rollout of its Stagwell Search+ platform. See our latest analysis for Stagwell. Stagwell’s recent AI launches, buyback expansion and investor conference appearances sit against a mixed share price record, with a 7 day share price return of 8.7% and a 1...

What recent returns say about Plug Power (PLUG) Plug Power (PLUG) has seen mixed share performance, with a 2.3% move over the past day, about 20% over the past week, a 5.1% gain over the past month, and a 1.4% decline over the past 3 months. See our latest analysis for Plug Power. At a share price of US$2.18, Plug Power’s recent 7 day share price return above 20% contrasts with a slightly negative year to date share price return and a very weak 3 year total shareholder return of around...

Recent share performance and business snapshot Berkshire Hathaway (BRK.B) has seen mixed recent returns, with a 3.5% gain over the past week, a 2.1% decline over the past month, and a modest 0.1% total return over the past year. Over longer horizons, total returns sit at 64.2% for the past 3 years and 95.3% for the past 5 years, while year to date performance is roughly flat at 0.1%. The company reports annual revenue of US$371.4b and net income of US$66.97b, with recent annual revenue growth...

IDEAYA Biosciences recently enrolled the first patient in its Phase 1 trial of IDE892 for MTAP-deleted solid tumors and outlined a refocused precision oncology pipeline, including combinations with its MAT2A inhibitor IDE397 and deprioritization of Trodelvy-related studies. A key insight is IDEAYA’s effort to build a coherent MTAP-deletion and CDKN2A-deficiency franchise, aiming to address genetically defined patient groups that currently lack targeted treatment options. Against this...

Eversource Energy (ES) is back in focus after its Q4 results and updated long term guidance, which included fresh 2026 EPS targets and a financing plan that limits potential equity dilution. See our latest analysis for Eversource Energy. The recent Q4 update and 2026 EPS guidance have come after a period where the share price has gained 9.6% over the past month and 8.9% over 90 days, while the 1 year total shareholder return of 25.1% signals that momentum has been building for some time. If...

Why Annaly Capital Management (NLY) is on income investors’ radar Annaly Capital Management (NLY) has drawn fresh attention after a recent share move, with the stock closing at US$22.19. This has prompted investors to reassess its income profile and recent return pattern. See our latest analysis for Annaly Capital Management. That latest move comes after a softer patch for the share price, with a 7 day share price return of 4.39% and a year to date share price decline of 3.10%, while the 1...

CF Industries Holdings (CF) is in focus as its clean energy push meets rising geopolitical risk in fertilizer markets, with attention on blue ammonia, carbon capture, and tightening urea supplies linked to the Middle East conflict. See our latest analysis for CF Industries Holdings. Recent trading reflects that story, with CF Industries Holdings posting a 19.9% 1 month share price return and a 44.8% 3 month share price return, contributing to a 47.4% 1 year total shareholder return. However,...

Pulse Biosciences recently reported long-term data from its first-in-human study of the nPulse Vybrance Percutaneous Electrode System, showing sustained benign thyroid nodule volume reduction over 15–22 months with no regrowth, no serious adverse events, and very high patient satisfaction. The data highlight nsPFA’s differentiated nonthermal ablation profile, with continued volume reduction over time and no intranodular fibrosis on ultrasound, suggesting potential durability for...

Why Zymeworks Stock Is Back in Focus After Q4 Updates Zymeworks (ZYME) is back on many investors’ watchlists after its Q4 earnings call highlighted progress for lead therapy zanidatumab, fresh regulatory milestones, and a sizable nondilutive funding deal with Royalty Pharma. See our latest analysis for Zymeworks. The recent Q4 update, stronger balance sheet after the Royalty Pharma deal, and ongoing analyst optimism appear to be feeding into Zymeworks’ recent momentum, with a 7 day share...

Why LGI Homes is on investors’ radar now LGI Homes (LGIH) has drawn attention after a period of weaker recent returns, including a 26.15% decline over the past month and a 41.79% total return decline over the past year. For investors tracking homebuilders, those moves, combined with annual revenue of US$1.71b and net income of US$72.55m, raise questions about how the business model and current valuation fit into a longer term portfolio view. See our latest analysis for LGI Homes. LGI Homes’...

Hasbro (HAS) has just completed a US$400 million senior notes offering with a 4.650% coupon due 2031 and extended its US$1.1 billion revolving credit facility to 2031, reshaping its funding profile. See our latest analysis for Hasbro. At a share price of US$95.78, Hasbro has seen a 19.9% 90 day share price return and a 55.2% 1 year total shareholder return. This suggests momentum has picked up even as the latest bond deal and headquarters move keep attention on balance sheet strength and...

Why Mercury Systems Is Back on Investors’ Radar Mercury Systems (MRCY) is drawing attention after sluggish order growth, falling operating margins, and pressure on earnings per share raised fresh questions about how durable its current business performance really is. See our latest analysis for Mercury Systems. At a share price of $89.36, Mercury Systems has seen a 24.35% 90 day share price return and a very strong 110.11% 1 year total shareholder return. This suggests momentum has been...